ArticleBMC ophthalmology2026
Hormone therapy preserves ocular surface integrity following circadian alignment disturbance in menopausal rats.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study examines the impact of a light-cycle shift regimen on corneal and conjunctival tissues in menopausal rats and evaluates the protective role of combined hormone therapy.
methodsTwenty-four menopausal female albino rats were randomly assigned to three groups (n = 8) following a 10-day acclimatization period. Group 1 (Control+Saline) was maintained under a 12:12 light/dark cycle. Light-cycle shift regimen was induced in Groups 2 and 3 using a rotating 7-day light-exposure sequence repeated over 21 days; this protocol consisted of 24 h of continuous light, 72 h of inverted dark-light timing, and 72 h of standard light-dark conditions. Groups 1 and 2 received saline, while Group 3 received 17β-Estradiol and drospirenone daily via oral gavage. After 31 days, eyes were enucleated for histological and immunohistochemical analyses of corneal, conjunctival, and palpebral tissues, including caspase-3 (Cas-3), tumor necrosis factor-alpha (TNF-α), and PERIOD-2 (PER2) expression.
resultsLight-cycle shift regimen (Group 2) significantly increased corneal thickness (p < 0.001), conjunctival inflammation, and vascular congestion, with marked upregulation of Cas-3 and TNF-α and downregulation of PER2. Hormone therapy (Group 3) attenuated these effects, showing reduced corneal edema, diminished inflammatory infiltration, and partial normalization of molecular markers.
conclusionsShifting light-dark cycles may aggravate inflammatory and apoptotic changes in the ocular surface during menopause. Estrogen-progestin therapy attenuates these alterations by modulating the expression of the circadian-associated protein PER2 and maintaining structural integrity. These findings suggest that hormone therapy may offer potential benefits for preserving ocular surface homeostasis in menopausal women experiencing sleep or circadian rhythm disturbances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.